Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams Pulls Off Trade For Mucinex Complement

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line
Advertisement

Related Content

Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March
Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS097858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel